This may explain some observed side effects of systemic long-term use of NR ligand therapies such as the PPAR agonist thiazolidinediones (TZDs) against diabetes (34, 35) or retinoids applied to treat skin diseases (36). Here, PPARA is linked to diabetes mellitus.